Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MARK2 encodes a member of the Par-1 family of serine/threonine protein kinases. Additionally we are shipping MAP/microtubule Affinity-Regulating Kinase 2 Proteins (10) and and many more products for this protein.
Showing 10 out of 111 products:
Human Monoclonal MARK2 Primary Antibody for ELISA, WB - ABIN560734
Hezel, Gurumurthy, Granot, Swisa, Chu, Bailey, Dor, Bardeesy, Depinho: Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. in Molecular and cellular biology 2008
Human Polyclonal MARK2 Primary Antibody for IHC (p), WB - ABIN392538
Blume-Jensen, Hunter: Oncogenic kinase signalling. in Nature 2001
Show all 2 Pubmed References
Human Polyclonal MARK2 Primary Antibody for IP, WB - ABIN4332738
Kruse, Krantz, Barker, Coletta, Rafikov, Luo, Højlund, Mandarino, Langlais: Characterization of the CLASP2 Protein Interaction Network Identifies SOGA1 as a Microtubule-Associated Protein. in Molecular & cellular proteomics : MCP 2017
Human Polyclonal MARK2 Primary Antibody for ELISA, WB - ABIN314316
Depasquale, Thompson: Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. in Histopathology 2008
In cell-based assays, Mark2 depletion indeed reduces Dvl (show DVL2 Antibodies) gene expression and interrupts neural stem cell (NSCs) growth and differentiation, which are likely to be mediated through a decrease in class IIa HDAC (show HDAC3 Antibodies) phosphorylation and reduced H3K4ac and H3K27ac occupancies at the Dvl1 (show DVL1 Antibodies)/2 promoters.
HIV-1 did not stimulate widespread FEZ1 (show LZTS1 Antibodies) phosphorylation but, instead, bound microtubule (MT) affinity-regulating kinase 2 (MARK2) to stimulate FEZ1 (show LZTS1 Antibodies) phosphorylation on viral cores.
Low expression of Mark2 is associated with uterine cervical neoplasms.
In this study, through quantitative analysis of the complex formation between CagA (show S100A8 Antibodies) and PAR1b, the authors found that several CagA (show S100A8 Antibodies) species have acquired elevated PAR1b-binding activity via duplication of the CagA (show S100A8 Antibodies) multimerization motifs, while others have lost their PAR1b-binding activity.
In the modeled structure of inactive MARK2, activation segment occludes the enzyme active site and assumes a relatively stable position.
In conclusion, baicalin and DDP (show TIMM8A Antibodies) were synergistic at inhibiting proliferation and invasion of human lung cancer cells at appropriate dosages and incubation time in the presence or absence of DDP (show TIMM8A Antibodies) resistance. The attenuation of DDP (show TIMM8A Antibodies) resistance was associated with downregulation of MARK2 and p-Akt (show AKT1 Antibodies).
MARK2 plays a role in promoting malignant phenotypes of lung cancer.
Phosphorylation of RNF41 (show RNF41 Antibodies) by Par-1b regulates basolateral membrane targeting of laminin-111 receptors.
induces asymmetric inheritance of plasma membrane domains via LGN (show GPSM2 Antibodies)-dependent mitotic spindle orientation in proliferating hepatocytes
Perturbation of PAR1b and SHP2 (show PTPN11 Antibodies) by CagA (show S100A8 Antibodies) underlies the oncogenic potential of CagA (show S100A8 Antibodies).
These results indicate that the basal localization of Par-1b in the outer epithelial cells is required for myoepithelial cell compression, and Par-1b is required for myoepithelial differentiation, regardless of its localization.
data suggest ectopic PAR1 (show F2R Antibodies) expression is not tolerated in mouse platelets and indicate a different approach is required to develop a small animal model for the purpose of any future preclinical testing of PAR (show AFG3L2 Antibodies) antagonists as anti-platelet drugs
a model whereby MARK2 negatively regulates insulin (show INS Antibodies) sensitivity in peripheral tissue through inhibition of KSR1 (show KSR1 Antibodies)
ROCK1 (show ROCK1 Antibodies)/PAR-1b-dependent regulation of basement membrane placement is required for the coordination of tissue polarity and the elaboration of tissue structure in the developing submandibular salivary gland.
PAR1b plays a novel role in the maintenance of mature dendritic spine morphology by regulating microtubule growth and the accumulation of p140Cap (show SRCIN1 Antibodies) in dendritic spines.
Par-1b is a regulator of glucose metabolism and adiposity in the whole animal
Interaction of MARK2 with CaMKI (show CAMK1 Antibodies) results in a novel, calcium-dependent pathway that plays an important role in neuronal differentiation.
Akt (show AKT1 Antibodies) enhances the activity of PAR1 (show F2R Antibodies) to promote tau hyperphosphorylation at S262/S356, a tau species that is not recognized by the CHIP/Hsp90 (show HSP90 Antibodies) complex
Coreduction of MARK2 and DCX (show DCX Antibodies) resulted in a partial restoration of the normal neuronal migration phenotype in vivo. The kinetic behavior of the centrosomes reflected the different molecular mechanisms activated when either protein was reduced.
This gene encodes a member of the Par-1 family of serine/threonine protein kinases. The protein is an important regulator of cell polarity in epithelial and neuronal cells, and also controls the stability of microtubules through phosphorylation and inactivation of several microtubule-associating proteins. The protein localizes to cell membranes. Multiple transcript variants encoding different isoforms have been found for this gene.
ELKL motif kinase 1
, PAR1 homolog b
, Ser/Thr protein kinase PAR-1B
, serine/threonine protein kinase EMK
, serine/threonine-protein kinase MARK2
, serine/threonine kinase